Janetta Trochimiuk, Principal Accounting Officer of PDS Biotechnology Corp, filed a Form 4 on November 17, 2026, disclosing the grant of an employee stock option on November 16, 2026.

Key Highlights

  • Option grant: Trochimiuk received an employee stock option (right to buy) covering 100,000 shares of common stock on November 16, 2026.
  • Exercise price: The option carries an exercise price of $0.9241 per share.
  • Expiration: The option expires on November 16, 2036.
  • Vesting schedule: Subject to stockholder approval, shares vest in equal monthly installments over four years beginning December 16, 2026, contingent on continued service.
  • Stockholder approval required: The option was granted subject to stockholder approval of the issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c) and is not exercisable until that approval is obtained.
  • Resulting ownership: Following the reported transaction, Trochimiuk directly holds 100,000 derivative securities (the option).

PDS Biotechnology Grants Principal Accounting Officer Conditional Stock Option

According to the Form 4 filed with the SEC on November 17, 2026, Janetta Trochimiuk, Principal Accounting Officer of PDS Biotechnology Corp (NASDAQ:PDSB), acquired an employee stock option (right to buy) covering 100,000 shares of common stock. The transaction date is listed as November 16, 2026, and the option was acquired at a price of $0.00, with an exercise price of $0.9241 per share and an expiration date of November 16, 2036.

The filing includes a notable condition: "The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained." The filing further states that if stockholder approval is not obtained pursuant to the terms of the grant, "the Reporting Person shall surrender the option to the Company for cancellation."

Contingent upon stockholder approval, the filing states that the shares subject to the option "shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date." Following the reported transaction, Trochimiuk's directly held derivative securities total 100,000. The option is reported as a direct ownership interest, with no indirect holdings noted in the filing.

What Was Disclosed

The filing disclosed a grant of a 100,000-share employee stock option to PDS Biotechnology's Principal Accounting Officer, Janetta Trochimiuk, at an exercise price of $0.9241, expiring November 16, 2036, and contingent on stockholder approval of the 2026 Equity Incentive Plan.